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Abstract 
Ischaemic injury impairs the integrity of blood-brain barrier (BBB). This study investigates 
the molecular causes of this defect with regards to the putative correlations amongst 
NAD(P)H oxidase, plasminogen-plasmin system components and matrix metalloproteinases. 
Hence, the activities of NAD(P)H oxidase, matrix metalloproteinase-2, urokinase- (uPA) and 
tissue-type plasminogen activators (tPA) alongside superoxide anion levels were assessed in 
human brain microvascular endothelial cells (HBMEC) exposed to oxygen-glucose 
deprivation alone or followed by reperfusion (OGD±R). The integrity of an in vitro model of 
BBB comprising HBMEC and astrocytes was studied by transendothelial electrical resistance 
and paracellular flux of albumin. OGD±R radically perturbed barrier function while 
concurrently enhancing uPA, tPA and NAD(P)H oxidase activities and superoxide anion 
release in HBMEC. Pharmacological inactivation of NAD(P)H oxidase attenuated OGD±R-
mediated BBB damage through modulations of matrix metalloproteinase-2 and tPA but not 
uPA activities. Overactivation of NAD(P)H oxidase in HBMEC via cDNA electroporation of 
its p22-phox subunit confirmed the involvement of tPA in oxidase-mediated BBB disruption. 
Interestingly, blockade of uPA or uPA receptor preserved normal BBB function by 
neutralizing both NAD(P)H oxidase and matrix metalloproteinase-2 activities. Hence, 
selective targeting of uPA after ischaemic strokes may protect cerebral barrier integrity and 
function by concomitantly attenuating basement membrane degradation and oxidative stress.  
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Introduction 
    Composed of brain microvascular endothelial cells surrounded by a basement membrane 
and astrocytic endfeet, the blood-brain barrier (BBB) regulates the passage of circulating 
substances into the brain parenchyma (Hayashi et al. 2004). Disruption of blood supply to the 
brain during ischaemic stroke evokes a cascade of deleterious events, such as depletion of 
ATP and acidosis, leading to disruption of the BBB (Hayashi et al. 2004, Brouns et al. 2009). 
Ensuing reperfusion of ischaemic tissue accompanied by excessive release of superoxide 
anion (O2
•–), a prominent reactive oxygen species, may exacerbate the damage to the BBB 
(Margaill et al. 2005, Selemidis et al. 2008, Walder et al. 1997).  
    Endothelial NAD(P)H oxidase represents the main source of O2
•– in ischaemic vasculature. 
It contains several cytosolic subunits and a membrane-bound cytochrome b558 consisting of 
gp91-phox and p22-phox, key subunits required for the enzymatic activity and stability as a 
whole (Kleikers et al. 2012, Kleinschnitz et al. 2010). While many studies have shown the 
significance of this enzyme complex in ischaemia-reperfusion injury (Eltzschig et al. 2004, 
Hong et al. 2006) the p22-phox subunit has not been studied significantly in this context.   
    In addition to O2
•–, the enhanced activation of serine proteases, namely tissue-type 
plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) along with their 
catalytic product plasmin may also compromise the BBB integrity under ischaemic 
conditions. The link between these serine proteases and ischaemic stroke is well established 
with studies showing both beneficial and detrimental roles (Cho et al. 2012, Hosomi et al. 
2001). The activities of plasminogen activators (PAs) are, amongst other mechanisms, 
controlled by the local availability of their inhibitors, namely plasminogen activator inhibitor-
1 (PAI-1) and in the case of uPA also by its specific receptor, uPAR (Irigoyen et al. 1999).  
    PAs have been linked to the levels and activities of MMPs namely MMP-2 and MMP-9 
during ischaemic stroke (Barr et al. 2010, Rosenberg et al. 1994, Thornton et al. 2008, Tsuji 
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et al. 2005). MMPs can be activated during different stages of a stroke, with emerging 
evidence indicating MMP-9 may have a more severe impact especially during the later stages 
(Asahi et al. 2000, Asahi et al. 2001a, Asahi et al. 2001b, Lucivero et al. 2007).  Recent 
studies have shown that deletion of both MMP-2 and -9 protects against cerebral infarction in 
mouse models (Suofu et al. 2012) and that these MMPs can contribute to BBB damage 
through degradation of the tight junction protein occludin (Liu et al. 2012).   
    In light of the above, the current study examined whether NAD(P)H oxidase-dependent 
release of O2
•– might compromise the integrity and function of an in vitro model of human 
BBB under ischaemic conditions through interactions with PAs and/or MMPs.  
    The study found that inhibition of uPA, NAD(P)H oxidase or MMP-2 exerts barrier-
protective effects. It also found that uPA acts upstream to both NAD(P)H oxidase and MMP-
2 thereby bestowing a significant therapeutic potential on this enzyme in maintaining BBB 
integrity and function. 
 
Methods 
Cell culture 
    Human brain microvascular endothelial cells (HBMEC) were purchased from ScienCell 
and grown to subconfluence in their specialised media before exposure to oxygen-glucose 
deprivation (OGD; 94.5% N2, 0.5% O2 and 5% CO2) or normoxia (N; 75% N2, 20% O2 and 
5% CO2) for 4 h. In some experiments, OGD was followed by 20 hours of reperfusion in that 
the ischaemic culture medium lacking glucose and FBS was replaced with fresh medium 
containing 5.5 mM glucose and 10% FBS before exposing cells to normoxic conditions. 
Similar experiments were carried out with the addition of amiloride (uPA inhibitor, 2.5 µM), 
apocynin (NAD(P)H oxidase inhibitor, 1 mM) or MMP-2 inhibitor III (2-((Isopropoxy)-(1,1’-
5 
 
 
biphenyl-4-ylsulfonyl)-amino)-H-hydroxyacetamide, 100 µM; Calbiochem) during the OGD 
or reperfusion stages.  
In vitro model of human BBB  
    Human astrocytes (ScienCell) were seeded onto the outer surface of Transwell inserts (0.4 
µm pore, Corning Costar) seated upside down and on the following day, HBMEC were 
seeded onto the inner surface of the same inserts. Both sets of cells were grown to confluence 
before exposure and/or treatment.  
Assessment of BBB permeability  
    The BBB integrity and function were studied, as previously described, by measurements of 
transendothelial electrical resistance (TEER) and the flux of Evan’s blue-labelled albumin 
(EBA, 67 kDa) across co-cultures, respectively (Allen et al. 2009a). TEER was measured 
using STX electrodes and an EVOM resistance meter (World Precision Instruments). To 
measure EBA flux, inserts were washed twice with Hank’s Balanced Salt Solution (HBSS) 
and then transferred to new 12-well plates containing 2 mL of HBSS. EBA (500 µL, 165 
µg/mL) was added to the luminal compartments and after 60 minutes samples were taken 
from both abluminal and luminal chambers. The concentration of dye in each chamber was 
determined by measuring the absorbance of the sample at 610 nm and flux was calculated 
(absorbance abluminal x 2000 x absorbance luminal-1).  
Immunoblotting  
    Equal amounts (40-60 µg) of protein were run on 10-15% SDS-polyacrylamide gels before 
transferring onto Hybond-P PVDF membrane (GE healthcare). The proteins were 
successively detected by primary antibodies specific for β-actin (mouse; synthetic β-
cytoplasmic actin N-terminal peptide; Sigma; cat. no. A5441; internal control; 1:10,000), p22-
phox (rabbit (FL-195); full length human p22-phox; Santa Cruz; cat. no. sc-20781; 1:200), 
PAI-1(rabbit (H-135); amino acids 24-158 of the N-terminus of human PAI-1; Santa Cruz; 
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cat. no. sc-8979; 1:750), tPA (rabbit (H-90); amino acids 1-90 of human tPA; Santa Cruz; cat. 
no. sc-15346; 1:300), uPA (rabbit (H-140); amino acids 136-275 of human uPA; Santa Cruz; 
cat. no. sc-14019; 1:500) or uPAR (rabbit (FL-290); full length human uPAR; Santa Cruz; 
cat. no. sc-10815;1:500) and infrared dye-tagged appropriate secondary antibodies (goat anti-
mouse and anti-rabbit; LI-COR Biosciences; cat. no. 926-68020 and 926-32211, respectively; 
1:30,000). The bands were scanned and analysed using the Odyssey Infrared Imaging System 
(LI-COR Biosciences). 
Cell viability 
    An aliquot of cells mixed with 0.1% Trypan blue was visualised under a light microscope. 
To calculate percentage viability, 100 cells were counted. 
Transfection experiments 
    HBMEC (~5x106) were re-suspended in 500 µl of media without FBS and antibiotics and 
stored on ice in a pre-chilled sterile cuvette. Anti-PAI-1 or anti-uPAR antibody (each 3 µg) or 
double-stranded p22-phox cDNA (50 ng) was added to the cell suspension and the mixture 
was electroporated at 1.8kV with an Easyjet Prima Electroporator (Equibio). Cells 
electroporated with equal volumes of vehicle (distilled H2O), control cDNA (28S rRNA) or a 
rabbit anti-IgG served as controls. Since electroporation reduced the viability rates by 
approximately 40%, the cell numbers were adjusted accordingly before seeding reasonably 
high numbers in flasks or on inserts to ensure all experimental groups reach confluence 
simultaneously. Cells were exposed to OGD and harvested within 3 days of transfection.  
Pyrogallol experiments 
    In some experiments, HBMEC alone or in co-culture with human astrocytes were exposed 
to pyrogallol (O2
•– generator, 2 µM) for a period of 3 days and fed twice a day with fresh 
medium containing pyrogallol. 
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Measurements of total O2•– levels and NAD(P)H oxidase activity 
    Total O2
•– levels were detected using the cytochrome C reduction assay as previously 
described (Allen et al. 2009a). Briefly, cell pellets were sonicated in cold lysis buffer (20 mM 
HEPES buffer, pH 7.2, 1 mM EGTA, 210 mM mannitol, 70 mM sucrose).  Equal amounts of 
homogenate (100 µg) were incubated with cytochrome C (50 µM) for 60 minutes at 37°C 
before absorbances were measured at 550 nm.   
    NAD(P)H oxidase activity was measured with the lucigenin chemiluminescence assay. 
Briefly, samples of homogenates (~100 µg) were incubated at 37°C in assay buffer (50 mM 
potassium phosphate buffer (pH 7.0), 1 mM EGTA, 150 mM sucrose, 5 µM lucigenin) 
containing the specific inhibitors for other reactive oxygen species-generating enzymes i.e. 
nitric oxide synthase (NG-nitro-L-arginine methyl ester, 100 µM), mitochondrial complex I 
(rotenone, 50 µM), xanthine oxidase (allopurinol, 100 µM) and cyclooxygenase 
(indomethacin, 50 µM). After 15 minutes NADH or NADPH (100 µM; Calbiochem) was 
added to initiate the reaction. The reaction was monitored every minute for 2 hours and the 
rate of reaction calculated. Buffer blanks were also run for both assays and subtracted from 
the data. 
Determination of PA activities 
    uPA and tPA activities were measured using an ELISA-based assay. Streptavidin coated 
plates (Thermo Scientific) were coated with biotinylated PAI-1 (300 ng/mL; Abcam) prior to 
addition of equal volumes of cell culture media or uPA and tPA standards (Calbiochem). 
Bound active uPA or tPA was then detected by successive incubations with the respective 
primary (see above; 1:50) and horseradish peroxidase-linked secondary antibodies (donkey 
anti-rabbit; Santa Cruz; cat. no. sc-2313; 1:5000). A colourimetric substrate, 3,3’,5,5’-
tetramethylbenzidine (Thermo Scientific), was added to the reaction before stopping it with 
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H2SO4. Absorbances were read at 450 nm and normalised against the respective standards and 
total protein concentrations.   
Gelatin Zymography  
    Total cell protein (20 µg) or culture media devoid of FBS used to grow HBMEC were run 
on 9% SDS-polyacrylamide gels containing 0.1% gelatin. MMP-2 and MMP-9 positive 
controls were also run on each gel. The gels were washed 3 times for 15 minutes in 2.5% 
Triton X-100 before incubating overnight at 37°C in buffer consisting of 50 mM Tris (pH 
7.5), 10 mM CaCl2, 150 mM NaCl and 0.05% Brij-35 (Calbiochem). Gels were then 
successively stained for 2 hours with 0.1% Coomassie blue dye in 25% methanol and 5% 
acetic acid and destained for 1 hour in 50% methanol and 10% acetic acid and then overnight 
in water. MMP activity was detected as clear bands and gels were scanned and analysed with 
the Odyssey Imaging System. 
Reagents 
All reagents unless specifically stated were from Sigma. 
Statistical analyses 
    Data are presented as mean±SEM from a minimum of 3 independent experiments. 
Statistical analyses were performed using one way ANOVA followed by a Tukey post hoc 
analysis or, where appropriate, by an independent Student’s t-test or a two way ANOVA 
followed by a Tukey post hoc test. p<0.05 was considered as significant. 
 
Results 
Effects of OGD and reperfusion on the BBB integrity and function  
    OGD alone and followed by reperfusion (OGD±R) impaired BBB integrity and function as 
confirmed by decreases in TEER and concurrent increases in EBA flux, respectively. The 
magnitudes of these changes were greater during the reperfusion phase. While inhibitions of 
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uPA and NAD(P)H oxidase restored barrier function in OGD±R, the inhibition of MMP-2 
appeared to be only effective during the reperfusion stage (data were analysed using two way 
ANOVA with a Tukey post hoc analysis: n≥3, F4.71=2.79, p<0.05; Figure 1A and n≥3, 
F4,36=5.37, p<0.03; Figure 1B).     
Effects of OGD±R on NAD(P)H oxidase  
    Exposures of HBMEC to OGD±R led to substantial increases in NAD(P)H oxidase activity 
and O2
•– levels which were effectively suppressed by attenuations of uPA and NAD(P)H 
oxidase but not MMP-2 activities (data were analysed using two way ANOVA with a Tukey 
post hoc analysis: n≥3, F4,112=1.68, p<0.05; Figure 2A and n≥3, F4,116=1.84, p<0.05; Figure 
2B). These imply that uPA and MMP-2 may act upstream and downstream to the oxidase, 
respectively. The increases in oxidase activity were mimicked by those observed in p22-phox 
protein expression, confirming the regulatory role of this particular subunit in determining 
overall enzyme activity (data were analysed using one way ANOVA with a Tukey post hoc 
analysis: n≥3, F2,6=9.65, p<0.05; Figure 2C). The difference in p22-phox expression between 
OGD and OGD+R groups cannot be attributed to reintroduction of glucose during the 
reperfusion phase as longer exposures to hyperglycaemia (≥3 days) are required to affect 
NADPH oxidase isoform protein expressions in HBMEC (Allen et al. 2009a, Shao et al. 
2013).  
O2•– impairs BBB integrity and increases tPA protein expression 
    To ascertain the contribution of O2
•– to BBB dysfunction, the co-cultures were treated with 
an O2
•– generator, pyrogallol which impaired the BBB integrity and function as evidenced by 
marked decreases in TEER (data analysed using one way ANOVA with Tukey post hoc: n≥3, 
F2,12=18.7, p<0.05; Figure 3A) and concomitant increases in paracellular flux (data analysed 
using one way ANOVA with Tukey post hoc: n≥3, F2,12=41.0, p<0.05; Figure 3B), 
respectively. Again, inhibition of uPA activity abolished O2
•–-mediated barrier damage (data 
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analysed using Student’s t-test: n≥3, p<0.05; Figure 3C) while pyrogallol enhanced tPA 
protein expression in HBMEC (data analysed using Student’s t-test: n≥3, p<0.05; Figure 3D). 
Taken together, these imply the presence of a differential crosstalk between specific PAs and 
O2
•–. 
Increased NAD(P)H oxidase activity amplifies tPA protein levels and BBB disruption 
    Having established the pivotal role of O2
•– in barrier damage, it was critical to unravel the 
involvement of NAD(P)H oxidase in this phenomenon. Hence, NAD(P)H oxidase activity 
was augmented in some HBMEC through electroporation of double-stranded p22-phox 
cDNA which significantly increased p22-phox protein levels and produced similar quantities 
of O2
•– as pyrogallol where the electroporation of control cDNA had no impact on NADPH 
oxidase activity or O2
•–  release. Inhibition of uPA activity with amiloride or by an anti-uPAR 
antibody normalised O2
•– levels and NAD(P)H oxidase activity. Electroporation with an anti-
IgG antibody did not reduce O2
•– levels or NAD(P)H oxidase activity (data analysed using 
one way ANOVA with Tukey post hoc: n≥3, F5,14=19.0, p<0.05; Figure 4A and n≥3, 
F5,15=14.3, p<0.05; Figure 4B and data analysed using Student’s t-test: n≥3, p<0.05; Figure 
4C). Specific increases in NAD(P)H oxidase activity also substantially increased tPA protein 
expression (data analysed using Student’s t-test: n≥3, p<0.05; Figure 4D). Inhibitions of uPA 
and uPA:uPAR binding through treatments with amiloride and an anti-uPAR antibody, 
respectively abolished all barrier-disruptive effects induced by p22-phox overexpression and 
ensuing NAD(P)H oxidase overactivity while electroporations of control cDNA or non-
specific isotype-matched antibody had no effect on barrier integrity or function (data analysed 
using one way ANOVA with Tukey post hoc: n≥3, F2,15=68.5, p<0.05; Figure 4E, n≥3, 
F2,6=0.92, p=ns; Figure 4G, n≥3, F2,11=85.77, p<0.05; Figure 4H and n≥3, F2,6=0.27, p=ns; 
Figure 4J and data analysed using Student’s t-test: n≥3, p=ns; Figure 4F and I).  
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Effects of OGD±R on MMP-2 and MMP-9 activities  
      Although dramatic increases in intracellular and secreted MMP-2 activities were obtained 
selectively during reperfusion phase of the ischaemic insult, the MMP-9 activity stayed below 
the level of detection in both OGD±R. As expected the MMP-2 inhibitor III normalised 
increases observed in MMP-2 activities (data analysed using one way ANOVA with Tukey 
post hoc: n≥3, F4,55=15.94, p<0.05; Figure 5A and n≥3, F5,79=6.96, p<0.05; Figure 5B). 
Inhibitions of uPA and NAD(P)H oxidase activities reversed the increases observed during 
reperfusion and affirmed the notion that both enzymatic systems operate upstream to MMP-2 
(data analysed using one way ANOVA with Tukey post hoc: n≥3, F4,58=17.58, p<0.05; Figure 
5C and n≥3, F5,83=7.27, p<0.05; Figure 5D). Interestingly, apocynin reduced the MMP-2 
activities in OGD alone-treated cells below the levels seen in control cells (data analysed 
using one way ANOVA with Tukey post hoc: n≥3, F4,59=32.71, p<0.05; Figure 5E and n≥3, 
F5,83=12.93, p<0.05; Figure 5F). As serum evokes an increase in secreted MMP-2 activity and 
was present during reperfusion phase of the experiments, two different controls were used to 
normalise secreted MMP-2 activities. N4h lacked serum and served as controls for OGD 
experiments while N20h containing equal amounts of serum served as controls for OGD+R 
groups. In order to illustrate the actual fold differences in enzymatic activities, both N4h and 
N20h values were normalised to “1”.  
Effects of OGD±R on plasminogen-plasmin system components 
    Similar to p22-phox protein, OGD±R also increased uPA, tPA and PAI-1 protein 
expressions without affecting that of uPAR in HBMEC (data analysed using one way 
ANOVA with Tukey post hoc: n≥3, F2,23=10.94, p<0.05; Figure 6A, n≥3, F2,33=0.70, p=ns; 
Figure 6B, n≥3, F2,24=10.46, p<0.05; Figure 6C and n≥3, F2,12=4.82, p<0.05; Figure 6E). The 
increases in uPA and tPA activities were somewhat reflective of those observed in the 
relevant protein expressions. To determine the putative regulatory effects of NAD(P)H 
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oxidase and MMP-2 on PA activities, the uPA and tPA activities were measured in HBMEC 
subjected to OGD±R in the absence or presence of apocynin or MMP-2 inhibitor III. While 
the inhibition of MMP-2 had no effect on either PA activities, the inactivation of NAD(P)H 
oxidase selectively suppressed the tPA activity. As expected, amiloride diminished OGD±R-
mediated increases seen in uPA but not tPA activity to the levels recorded in control cells 
(data analysed using one way ANOVA with Tukey post hoc: n≥3, F8,18=14.55, p<0.05; Figure 
6D and n≥3, F8,19=8.56, p<0.05; Figure 6F). 
PAs contribute to BBB damage during 20 h of OGD 
    To consolidate the specific contributions of PAs to the barrier damage, co-cultures were 
established using HBMEC transfected with anti-uPAR or anti-PAI-1 antibody to quench uPA 
activity and enhance overall PA activities, respectively. Electroporation of anti-PAI-1 
antibody impaired barrier integrity and function under normoxic and 20 h OGD compared to 
corresponding anti-uPAR antibody and control groups. In contrast, electroporation of anti-
uPAR antibody did not affect BBB integrity under normoxic and ischaemic conditions 
compared to controls (data analysed using one way ANOVA with Tukey post hoc: n≥3, 
F7,26=40.18, p<0.05; Figure 7A and n≥3, F7,24=35.49, p<0.05; Figure 7B). To confirm tPA and 
uPA were being affected the PA activities were also measured after the above transfections. 
As expected electroporation with anti-PAI-1 antibody increased both tPA and uPA activities 
in both control and 20 h OGD groups. Transfection with anti-uPAR antibody had no effect on 
tPA activity but did decrease uPA activity in control and 20 h OGD groups. The use of an 
anti-IgG control had no effect on PA activities (data analysed using one way ANOVA with 
Tukey post hoc: n≥3, F7,25=28.34, p<0.05; Figure 7C and n≥3, F7,26=16.46, p<0.05; Figure 
7D).   
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Discussion 
    The BBB serves as a highly selective, yet permeable, barrier between systemic circulation 
and the central nervous system. Several pathologies, including ischaemic injury, compromise 
its integrity therefore allowing leakage of circulating molecules into the brain and triggering 
formation of vasogenic oedema as a consequence, the main cause of death within the first 
week after a stroke (Hayashi et al. 2004). Microvascular endothelial cells constitute the main 
cellular component of the BBB due to their ability to express many tight junction proteins, 
notably occludin and claudin-5, to prevent vascular permeability. Since endothelial cells 
express and retain these proteins only when co-cultured with astrocytes (Persidsky et al. 2006, 
Hayashi et al. 1997), a contact co-culture model of human BBB comprising HBMEC and 
human astrocytes was used during the current study. This model showed normoxic TEER 
values which are consistent with similar endothelial cell models reported previously and 
mimicked the characteristics of the BBB and displayed significant physical and functional 
impairments when subjected to OGD±R as evidenced by marked decreases in TEER and 
simultaneous increases in paracellular flux, respectively (Allen et al. 2009a, Allen et al. 
2010).  
    As well as being the primary cells to form cerebral barrier, endothelial cells can act as key 
generators of O2
•– in acute ischaemic settings to initiate or worsen cerebrovascular injury 
(Raat et al. 2009, Chrissobolis et al. 2008). Indeed, exposure of HBMEC to OGD±R in the 
present study led to substantial increases in O2
•– production which was attributed to the 
enhanced NAD(P)H oxidase activity during a clinically-relevant period of experimental 
ischaemia, 4 hours OGD alone or followed by reperfusion (Hacke et al. 2004). Although high 
concentrations of peroxidisable lipids, low antioxidant capacity and reactions involving 
glutamate oxidation may further explain the susceptibility of cerebral barrier to prolonged 
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oxidative injury, putative contributions of mechanisms functionally intertwined with 
NAD(P)H oxidase cannot be fully dismissed in this context (Allen et al. 2009b).  
   Recent studies with matrix-degrading proteolytic enzymes have implicated PAs in cerebral 
barrier disruption because of their ability to digest the basal lamina around the capillaries or 
modulate MMP-2 activity via their end-product, plasmin (Baramova et al. 1997). Consistent 
with previous studies reporting higher proteolytic activity in mice after induction of focal 
cerebral ischaemia, significant increases have also been observed in the expressions and/or 
activities of tPA, uPA and PAI-1 in HBMEC following exposures to OGD±R (Ahn et al. 
1999, Hosomi et al. 2001, Wang et al. 1998). Similar levels of uPAR expression in HBMEC 
before and after application of ischaemic insult imply adequate existence of this receptor on 
cerebral endothelial cells to realise full uPA proteolytic activity (Wang et al. 2003) and the 
continuing high level of uPA activity despite high PAI-1 levels in the same conditions  may 
be due to its resistance to inhibition once complexed with uPAR (Higazi et al. 1996).  
    In terms of MMP activities, while dramatic increases were recorded in intracellular and 
secreted activities of MMP-2 only after induction of reperfusion, the activity of MMP-9 
stayed below the detection threshold of gelatin zymography throughout (Tahanian et al. 2011, 
Cavdar et al. 2010). Similar to recent studies (Suofu et al. 2012) attenuation of MMP-2 
activity with MMP-2 inhibitor III showed improvement in both barrier integrity and function 
during the reperfusion stage. Since MMP-2 activity was not found to be increased during 
OGD alone it is not surprising that inhibition of MMP-2 during OGD did not have a 
beneficial impact. A dose dependence study was conducted with MMP-2 inhibitor III and 100 
nM selected, as further increasing the dose had no effect in reducing MMP-2 activity further 
during OGD±R (data not shown). To determine the actual relevance of NAD(P)H oxidase 
activity to the OGD±R-mediated activations of MMP-2 and PAs, in some experiments the 
oxidase activity was quenched by apocynin, which has previously been shown to reduce 
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NAD(P)H oxidase activity in endothelial cells (Bayraktutan, 2004). Apocynin significantly 
suppressed MMP-2 and tPA activities without affecting that of uPA. Taken together these 
data suggest that NAD(P)H oxidase operates downstream to uPA and upstream to tPA and 
MMP-2. The severity of BBB damage during reperfusion, where MMP-2 activity and O2
•– 
levels are at their highest, further confirm the existence of a close link between MMP-2 and 
NAD(P)H oxidase. Furthermore, the attenuation of constitutive MMP-2 activities in cells 
exposed to OGD alone, may indicate the O2
•–-independent beneficial effects emerged from 
targeting of NAD(P)H oxidase (Chen et al. 2011, Chen et al. 2009).  
    Having deduced that uPA may sit at the helm of oxidative stress-related BBB damage that 
emerge during ischaemic injury, the effects of uPA inhibition with amiloride on barrier 
integrity, MMP-2 and NAD(P)H oxidase activities and O2
•– generation, were tested in 
OGD±R. A dose dependence study was conducted and 2.5 µM was observed to be effective 
in normalising uPA activity under OGD±R (data not shown). At lower concentrations, 
amiloride acts as a specific inhibitor of uPA and displays no effect on tPA expression and 
activity despite being able to inhibit angiogenesis, capillary morphogenesis and Na+/H+ 
exchange pathway at considerably higher concentrations, ≥130 M (Haworth et al. 1993). 
Similar to treatments with apocynin, amiloride selectively suppressed O2
•– release and 
NAD(P)H oxidase activity in cells exposed to OGD±R, affirming the supposed regulatory 
effect of uPA on NAD(P)H oxidase activity. Again, like apocynin, it attenuated reperfusion-
mediated increases in intracellular and secreted MMP-2 activities. Amiloride also improved 
the physical and functional aspects of the BBB in the same settings.  
    To discover the specific contributions of PAs to OGD-evoked BBB damage, the 
intracellular levels of both PAs and uPA alone were manipulated by electroporation of anti-
PAI-1 or anti-uPAR antibodies into HBMEC before establishing and exposing co-cultures to 
a condition that yields considerable barrier damage i.e. 20 hours of OGD alone (Allen et al. 
16 
 
 
2010). These revealed that selective increases in total PA activity but not tPA activity alone 
led to severe impairments in the BBB integrity and function under both normoxic and 
ischaemic conditions. Part of the modulation of uPAR function involves the internalisation of 
the uPA-PAI-1- uPAR complex. Once internalised, the uPA-PAI-1 complex dissociates from 
uPAR and is transferred to the lysosomes while the free uPAR returns to the plasma 
membrane. To suppress this recycling which regulates uPAR signalling, in these experiments 
the uPAR antibody was introduced into the cells. The use of a relatively high, but nontoxic, 
concentration of anti-uPAR IgG (3 g) ensured concurrent neutralisation of uPAR on the 
plasma membrane as well.  
    Despite exaggerated release of O2
•–, treatments of acute ischaemic stroke patients with free-
radical scavengers produced somewhat contradictory results -beneficial versus neutral- in 
terms of lesion volume regression and clinical outcomes (Shuaib et al. 2007, Nakase et al. 
2011). To explore the specific involvements of NAD(P)H oxidase and O2
•– on barrier 
integrity and function and also to assess the therapeutic role of interventions with uPA 
activity, the levels of enzyme activity and O2
•– availability were elevated in HBMEC through 
electroporation of p22-phox cDNA and treatments with pyrogallol, respectively (Ear et al. 
2001). Both applications produced pathologically relevant quantities of O2
•–, similar to the 
levels observed after 4 OGD±R, and evoked substantial impairments in the BBB integrity and 
function. Similar to ischaemic insult, elevations in NAD(P)H oxidase activity and ensuing 
O2
•– release also increased the protein expressions of tPA. Attenuation of uPA proteolytic 
activity by amiloride or cessation of its binding to uPAR, a prerequisite for enzyme activity 
(Fuhrman et al. 2008) completely abolished these changes. 
    In conclusion, the data presented in the current study suggest that suppression of uPA 
activity may protect cerebral barrier against ischaemia-reperfusion injury by subduing MMP-
17 
 
 
2 activity in a direct fashion or through attenuation of NAD(P)H oxidase-dependent O2
•–
generation.  
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Figure legends 
FIG. 1. The effects of OGD±R on the blood-brain barrier integrity and function. Human 
brain microvascular endothelial cell-human astrocyte co-cultures were exposed to 4 hours of 
oxygen-glucose deprivation alone (OGD) and followed by 20 hours of reperfusion (OGD+R) 
with and without inhibitors for urokinase-type plasminogen activator, amiloride; NAD(P)H 
oxidase, apocynin and matrix metalloproteinase-2, MMP-2 inhibitor III.  OGD alone and 
OGD+R presented a significant decrease in transendothelial electrical resistance (TEER) and 
concurrent increase in Evan’s blue albumin (EBA) flux. Treatments with amiloride and 
apocynin increased TEER values (A) and decreased EBA flux volumes (B) in all conditions 
compared to untreated groups. Treatment with MMP-2 inhibitor III increased TEER values 
and decreased EBA flux volumes during the reperfusion stage only. Data are expressed as 
mean±SEM from n≥3 and were analysed using a two way ANOVA followed by a Tukey post 
hoc test. *, † and ‡ p<0.05 vs normoxia (N), 4 hours of OGD and corresponding untreated 
cells, successively. 
 
FIG. 2. The effects of OGD±R on NAD(P)H oxidase system. Human brain microvascular 
endothelial cells were exposed to 4 hours of oxygen-glucose deprivation alone (OGD) and 
followed by 20 hours of reperfusion (OGD+R) with and without inhibitors for urokinase-type 
plasminogen activator, amiloride; NAD(P)H oxidase, apocynin and matrix metalloproteinase-
2, MMP-2 inhibitor III. NAD(P)H oxidase activity (A), total O2
•– levels (B) and p22-phox 
protein expression (C) were significantly increased after OGD±R compared to controls. 
Treatments with amiloride and apocynin normalised total O2
•– levels and NAD(P)H oxidase 
activity during ODG±R while treatments with MMP-2 inhibitor III proved to be ineffective. 
Data are expressed as mean±SEM from n≥3 and were analysed using a two way ANOVA 
followed by a Tukey post hoc test for (A-B) and a one way ANOVA followed by Tukey post 
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hoc test for (C). *, † and ‡ p<0.05 vs normoxia (N), 4 hours of OGD and corresponding 
untreated cells, successively.  
 
FIG. 3. The effects of pyrogallol on TEER, EBA flux and tPA protein levels. Human 
brain microvascular endothelial cell-human astrocyte co-cultures were exposed to pyrogallol 
with and without and inhibitor for urokinase-type plasminogen activator, amiloride. Exposure 
to pyrogallol significantly impaired BBB integrity as shown by decreases in transendothelial 
electrical resistance (TEER) and increases in Evan’s blue albumin (EBA) flux volumes which 
were normalised by amiloride (A-B). Pyrogallol significantly increased total superoxide 
anion (O2
•–) levels (C) and tissue-type plasminogen activator (tPA) protein levels (D) in 
endothelial cells. Data are expressed as mean±SEM from n≥3 and were analysed using a one 
way ANOVA followed by Tukey post hoc test for (A-B) a Student’s t-test for (C-D). *p<0.05 
vs control and †p<0.05 vs pyrogallol-treated cells. 
 
FIG. 4. The effect of p22-phox cDNA transfection on NAD(P)H oxidase system, tPA 
protein levels and blood-brain barrier. Human brain microvascular endothelial cells 
transfected with p22-phox or control cDNA cultured alone or with human astrocytes. Cells 
were then exposed to amiloride, a urokinase-type plasminogen activator (uPA) inhibitor, or 
concurrently transfected with an anti-uPA receptor (uPAR) or anti-IgG antibody. Transfection 
markedly increased NAD(P)H oxidase activity and total superoxide anion (O2
•–) levels 
compared to controls which were normalised by treatments with amiloride or anti-uPAR 
antibody. Transfection with vehicle, control cDNA or anti-IgG antibody had no effect on 
NAD(P)H oxidase activity or O2
•– levels (A-B). p22-phox cDNA transfection led to 
significant increases in both p22-phox and tissue-type plasminogen activator (tPA) protein 
expressions (C-D). Treatments with amiloride and transfection of anti-uPAR antibody 
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abolished p22-phox cDNA transfection-mediated changes in the blood-brain barrier integrity 
(E-G) and function (H-J). Data are expressed as mean±SEM from n≥3 and were analysed 
using a one way ANOVA followed by Tukey post hoc test for (A-B, E, G-H and J) and a 
Student’s t-test for (C-D, F and I). *p<0.05 vs vehicle and control cDNA and †p<0.05 vs p22-
phox cDNA-transfected cells. 
 
FIG. 5. The effects of OGD±R on intracellular and secreted MMP-2 activities. Human 
brain microvascular endothelial cells were exposed to 4 hours of oxygen-glucose deprivation 
alone (OGD) and followed by 20 hours of reperfusion (OGD+R) with and without inhibitors 
for urokinase-type plasminogen activator, amiloride; NAD(P)H oxidase, apocynin and matrix 
metalloproteinase-2 (MMP-2), MMP-2 inhibitor III. In the normoxia groups cells were 
exposed to cell culture media for either 4 or 20 hours to correspond to 4 hours in OGD or 20 
hours of reperfusion. OGD+R, but not OGD alone, caused significant elevations in 
intracellular and secreted MMP-2 activities in brain microvascular endothelial cells (A-F). 
While treatments with apocynin significantly reduced intracellular and secreted MMP-2 
activities in all conditions (E-F), the inhibitory effects of amiloride were confined to OGD+R 
groups (C-D). Data are expressed as mean±SEM from n≥3 and were analysed using a one 
way ANOVA followed by Tukey post hoc test. *, † and ‡ p<0.05 vs normoxia groups (N4h or 
N20h), 4 hours of OGD and corresponding untreated cells, successively. 
 
FIG. 6. The effects of OGD±R on plasminogen-plasmin system components. Human brain 
microvascular endothelial cells were exposed to 4 hours of oxygen-glucose deprivation alone 
(OGD) and followed by 20 hours of reperfusion (OGD+R) with and without inhibitors for 
urokinase-type plasminogen activator, amiloride; NAD(P)H oxidase, apocynin and matrix 
metalloproteinase-2, MMP-2 inhibitor III. OGD±R evoked significant increases in 
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plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (tPA) and 
urokinase-type plasminogen activator (uPA) protein levels and/or activities without affecting 
that of uPAR, uPA receptor (A-F). Treatments with apocynin normalised tPA activity but 
failed to affect uPA activity. MMP-2 inhibitor III did not affect tPA and uPA activities. uPA 
but not tPA activity was effectively suppressed by amiloride confirming the ability of this 
drug to attenuate uPA activity alone (D and F). Data are expressed as mean±SEM from n≥3 
and were analysed using a one way ANOVA followed by Tukey post hoc test. *, † and ‡ 
p<0.05 vs normoxia (N), 4 hours of OGD and corresponding untreated cells, successively.  
 
FIG. 7. The effects of anti-PAI-1 and anti-uPAR antibody transfection on blood-brain 
barrier. Human brain microvascular endothelial cells transfected with anti-plasminogen 
activator inhibitor-1 (PAI-1) or anti-urokinase-type plasminogen activator receptor (uPAR) 
antibodies were co-cultured with human astrocytes and exposed to 20 hours of oxygen-
glucose deprivation (OGD). Exposures to extended periods of OGD led to significant 
disruption of the blood-brain barrier as evidenced by decreases in TEER, transendothelial 
electrical resistance (A) and increases in Evan’s blue albumin (EBA) flux (B). The 
magnitudes of these changes were greater in co-cultures established with anti-PAI-1 
antibody-transfected endothelial cells. In contrast, co-cultures established with anti-uPAR 
antibody-transfected endothelial cells displayed similar TEER or EBA flux when compared 
to vehicle-transfected (distilled H2O) controls (A-B). Both tPA and uPA activities were 
increased after 20 h OGD and further increased in endothelial cells transfected with anti-PAI-
1 antibody.  Transfection with anti-uPAR antibody had no effect on tPA activity but reduced 
uPA activity in normoxic and 20 h OGD exposed cells. Transfection with an anti-IgG 
antibody had no effect on PA activities (C-D). Data are expressed as mean±SEM from n≥3 
and were analysed using a one way ANOVA followed by Tukey post hoc test. *, †, ‡ and § 
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p<0.05 vs vehicle transfected normoxia (N), vehicle transfected 20 hours OGD, anti-PAI-1 
transfected normoxia and anti-PAI-1 transfected 20 hours OGD, successively. 
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